We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

Opens in a new tab or window Few medications have had such a meteoric rise as semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound), the GLP-1-based treatments for obesity that have captivated ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Zepbound works by activating the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors to mimic hormones that occur in the body after eating. As with Ozempic and Wegovy ...

AAA is famous for its travel reports, and for the first time ever, it's releasing a cruise forecast for 2025. “This look is ...

A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous Brenton Blanchet is a writer-reporter at PEOPLE. He has been working at PEOPLE ...